23andme Holding Co Revenue per Employee (ME), current and historic results, rankings and more, quarterly fundamentals - CSIMarket
CSIMarket
 


23andme Holding Co  (ME)
 

23andme Holding Co's Revenue per Employee

Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales


23andme Holding Co's Revenue per employee fell on a trailing twelve month basis to $ 299,003, below the company average number of $422,954.
Within the Healthcare sector Employees of 241 other companies have achieved higher revenue per employee. While revenue/employee total ranking has improved so far to 1880, from total ranking in previous quarter at 2151. 23andme Holding Co has 582 employees.


What is Sales per Employee Ratio?







ME Revenue per Employee (Jun 30 2025)
I. Quarter
(Mar 31 2025)
IV. Quarter
(Dec 31 2024)
III. Quarter
(Sep 30 2024)
II. Quarter
(Jun 30 2024)
I. Quarter
Y / Y Revenue Change -37.92 % -28.87 % 36.17 % -12.71 % -34.88 %
Sales per Employee (TTM) $ 299,003 324,749 357,009 329,706 340,569
ME's Total Ranking # 1880 # 2151 # 713 # 1777 # 1175
Seq. Revenue Change -46.97 % -22.68 % 37.83 % 9.85 % -39.24 %


Revenue per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 107
Healthcare Sector # 242
Overall Market # 1880

Revenue per Employee Statistics
High Average Low
$ 528,644 $ 422,954 $ 299,003
(Dec 31 2022)   (Jun 30 2025)



Financial Statements
23andme Holding Co's Revenue MRQ $ 25 Millions Visit ME's Income Statement
23andme Holding Co's Revenues TTM $ 174 Millions Visit ME's aggregate revenue growth
What are ME's Sales? Visit ME's Sales by Segment


  News about 23andme Holding Co Revenue per employee

23andMe Expands Genetic Insights Amidst Reverse Stock Split Announcement

23andMe Holding Co. a leader in personal genomics and biotechnology, has made significant advancements in the services it offers to its premium members while concurrently implementing strategic corporate financial adjustments. This article provides an overview of the company s new genetic reports and its recent decision to undergo a reverse stock split. Genetic Reporting Innovations 23andMe has launched a new genetic report that aims to provide valuable insights into the genetic predisposition for developing osteoporosis. This report, available exclusively to 23andMe+ Premium members, utilizes a comprehensive analysis of thousands of genetic variants. Osteoporosis, a condition characterized by decreased bone density and increased fracture risk, can significantly impact quality of life, especially in the aging population. By offering personalized reports based on individual genetic profiles, 23andMe empowers its members to better understand their health risks, potentially enabling more informed decisions about lifestyle and medical interventions.




Other Ratios
23andme Holding Co's Income per Employee
Employees in Major Pharmaceutical Preparations
Major Pharmaceutical Preparations Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
ME's Revenue per Employee versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for ME's Competitors
Revenue per Employee for ME's Suppliers
Revenue per Employee for ME's Customers

You may also want to know
ME's Sales Growth Rates ME's Pe Price to earnings ratio ME's Receivables Turnover Ratio ME's Stock Quote
ME's Net Income Growth Rates ME's Ps Price to Sales ratio ME's Sales per Employee ME's Asset Turnover Ratio
ME's Net Margin ME's Pb Price to Book ratio ME's Financial Strength Ratios ME's Dividend Payout Ratio
Date modified: 2026-08-29T17:43:38+00:00




Companies with similar Revenue per Employee for 12 months ending Jun 30 2025, within Healthcare Sector Revenue per Employee Revenue 12 months ending Jun 30 2025Number of Employees Jun 30 2025
Iridex Corp  523,075.27 $ 48.646  Million 93 
Entrada Therapeutics Inc   522,868.42 $ 79.476  Million 152 
Cervomed Inc   518,464.53 $ 7.777  Million 15 
Biofrontera Inc   516,532.61 $ 47.521  Million 92 
Nutriband Inc   515,611.80 $ 2.578  Million
Instil Bio Inc   514,764.71 $ 8.751  Million 17 
Henry Schein Inc   510,920.00 $ 12,773.000  Million 25,000 
Mannkind Corporation  509,689.19 $ 301.736  Million 592 
Skinhealth Systems Inc   505,199.02 $ 309.687  Million 613 
Koru Medical Systems Inc   504,773.30 $ 36.848  Million 73 
Orthofix Medical Inc   504,078.50 $ 809.046  Million 1,605 
Organogenesis Holdings Inc   502,963.70 $ 429.531  Million 854 
Bionexus Gene Lab Corp   502,713.63 $ 9.552  Million 19 
Nexgel Inc   500,947.37 $ 9.518  Million 19 
Phibro Animal Health Corporation  497,482.53 $ 1,295.942  Million 2,605 
Maravai Lifesciences Holdings Inc   496,213.79 $ 215.853  Million 435 
Avantor Inc   493,762.96 $ 6,665.800  Million 13,500 
Biolife Solutions Inc   493,606.45 $ 76.509  Million 155 
Allurion Technologies Inc   492,292.68 $ 20.184  Million 41 
Si bone inc   489,845.74 $ 184.182  Million 376 
Teva Pharmaceutical Industries Limited  489,808.54 $ 16,629.000  Million 33,950 
Bausch Health Companies Inc   485,615.76 $ 9,858.000  Million 20,300 
Ginkgo Bioworks Holdings Inc   475,907.22 $ 230.815  Million 485 
Curis Inc   475,208.33 $ 11.405  Million 24 
Treace Medical Concepts Inc   475,002.22 $ 213.751  Million 450 
Viatris Inc   470,523.33 $ 14,115.700  Million 30,000 
Iradimed Corporation  467,681.70 $ 77.635  Million 166 
Zymeworks Inc   465,405.30 $ 122.867  Million 264 
Alpha Pro Tech Ltd   465,024.39 $ 57.198  Million 123 
Zimmer Biomet Holdings Inc   460,811.76 $ 7,833.800  Million 17,000 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.